{
    "name": "Rx plus preferred drug list",
    "number": "312.5",
    "text": "(a)\u00a0 The department shall establish an Rx plus preferred drug list that includes but is not limited to:\n\u00a0\u00a0\u00a0\u00a0 (1)\u00a0 Drugs listed on the State's medicaid preferred drug list;\n\u00a0\u00a0\u00a0\u00a0 (2)\u00a0 Antipsychotic drugs;\n\u00a0\u00a0\u00a0\u00a0 (3)\u00a0 Antidepressant drugs;\n\u00a0\u00a0\u00a0\u00a0 (4)\u00a0 Chemotherapy drugs;\n\u00a0\u00a0\u00a0\u00a0 (5)\u00a0 Antiretroviral drugs;\n\u00a0\u00a0\u00a0\u00a0 (6)\u00a0 Immunosuppressive drugs; and\n\u00a0\u00a0\u00a0\u00a0 (7)\u00a0 Any other drugs listed on the Rx plus preferred drug list pursuant to this section.\n\u00a0\u00a0\u00a0\u00a0 (b)\u00a0 The pharmacy and therapeutic committee shall review and recommend drugs for placement on the Rx plus preferred drug list, striving to identify the safest and most efficacious drugs that are available at the lowest cost.\u00a0 The committee's recommendations may take into consideration any of the following factors:\n\u00a0\u00a0\u00a0\u00a0 (1)\u00a0 Therapeutic value for the disease or condition under treatment;\n\u00a0\u00a0\u00a0\u00a0 (2)\u00a0 Clinical efficacy;\n\u00a0\u00a0\u00a0\u00a0 (3)\u00a0 Safety;\n\u00a0\u00a0\u00a0\u00a0 (4)\u00a0 Cost; and\n\u00a0\u00a0\u00a0\u00a0 (5)\u00a0 Other relevant factors as determined by the committee.\n\u00a0\u00a0\u00a0\u00a0 (c)\u00a0 When considering categories of drugs designed to treat specialized chronic medical conditions and diseases, the committee shall consult with physicians and other health care professionals with specialized clinical knowledge and expertise in this area, either in their capacity as consultants serving on a subcommittee of the committee, or as physicians or pharmacists with a practice or specialty in chronic diseases.\n\u00a0\u00a0\u00a0\u00a0 (d)\u00a0 The determination of a drug's safety and efficacy shall be consistent with the standards set forth in the peer-reviewed literature and other available sources, including but not limited to:\n\u00a0\u00a0\u00a0\u00a0 (1)\u00a0 The American Hospital Formulary Service Drug Information;\n\u00a0\u00a0\u00a0\u00a0 (2)\u00a0 The United States Pharmacopoeia Drug Information;\n\u00a0\u00a0\u00a0\u00a0 (3)\u00a0 The DRUGDEX System; and\n\u00a0\u00a0\u00a0\u00a0 (4)\u00a0 The American Medical Association Drug Evaluations.\n\u00a0\u00a0\u00a0\u00a0 (e)\u00a0 The determination of a drug's net cost shall consider the pharmacy reimbursement amount authorized under section 346-317, as adjusted by manufacturer's rebates to be paid to the department.\u00a0 The committee shall determine that a drug has no significant clinical or safety advantages over one or more alternative drugs when used for a given purpose before it may consider the drug's net cost. [L 2004, c 47, pt of \u00a71; am L 2005, c 22, \u00a720]"
}